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CASE STUDY
Targeting vivax malaria in the Asia 
Pacific: The Asia Pacific Malaria Elimination 
Network Vivax Working Group
The Vivax Working Group*
Abstract 
The Asia Pacific Malaria Elimination Network (APMEN) is a collaboration of 18 country partners committed to elimi-
nating malaria from within their borders. Over the past 5 years, APMEN has helped to build the knowledge, tools and 
in-country technical expertise required to attain this goal. At its inaugural meeting in Brisbane in 2009, Plasmodium 
vivax infections were identified across the region as a common threat to this ambitious programme; the APMEN Vivax 
Working Group was established to tackle specifically this issue. The Working Group developed a four-stage strategy 
to identify knowledge gaps, build regional consensus on shared priorities, generate evidence and change practice to 
optimize malaria elimination activities. This case study describes the issues faced and the solutions found in develop-
ing this robust strategic partnership between national programmes and research partners within the Working Group. 
The success of the approach adopted by the group may facilitate similar applications in other regions seeking to 
deploy evidence-based policy and practice.
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Background
The importance of Plasmodium vivax in elimination
Once regarded as a relatively benign infection, Plasmo-
dium vivax is now acknowledged to be an important 
public health threat, capable of causing life-threatening 
disease complications, debilitating recurrent infections, 
miscarriage and chronic infections [1–6]. The increas-
ing sensitivity of diagnostic tools [7] has significantly 
improved the understanding of current P. vivax epidemi-
ology and it has become apparent that the true burden of 
vivax malaria infections is significantly higher than pre-
viously assumed [8]. Furthermore, although major gains 
have been made in the reduction of malaria over the last 
decade [9], in almost all co-endemic regions these suc-
cesses are far greater for Plasmodium falciparum than 
for P. vivax. Compared with P. falciparum, P. vivax exhib-
its far more extensive genetic diversity [10–13] and has 
numerous adaptive biological mechanisms, such as the 
ability to develop dormant liver stages (hypnozoites) 
and the emergence of transmissible blood stages (game-
tocytes) before clinical symptoms [14]. These properties 
afford the parasite a variety of strategies to adapt to envi-
ronmental challenges, including those imposed by inten-
sive malaria control activities.
The adaptability of P. vivax makes it difficult to con-
tain and highly prone to resurgence especially when con-
trol efforts cannot be sustained [15]. Hence, treating all 
stages of the parasite (radical cure) is a critical strategy 
for the successful control and ultimate elimination of P. 
vivax. Radical cure of P. vivax requires clearance of blood 
stage parasites as well as the hypnozoites, which result in 
relapse and re-establishment of a blood stage infection. 
Chloroquine has remained the preferred treatment for 
P. vivax blood stage infections in most endemic coun-
tries, however this policy is under threat from emerg-
ing drug resistant P. vivax strains [16]. The only current 
widely available drug with activity against hypnozoites is 
the 8-aminoquinoline compound, primaquine. Unfortu-
nately, individuals who have a genetic deficiency in the 
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enzyme glucose-6-phosphate dehydrogenase (G6PD) are 
at risk of severe haemolysis when treated with the drug 
[17]. In addition, primaquine requires prolonged daily 
administration over seven to 14  days. The complexities 
of prescribing reliable, safe and effective radical cure of 
P. vivax highlights the urgent need for innovative new 
approaches to assure schizonticidal and hypnozoiticidal 
treatment; without both activities, P. vivax elimination is 
unnecessarily delayed or unlikely in most settings.
APMEN history
The Asia Pacific Malaria Elimination Network (APMEN) 
was established in 2009 to create an innovative, country-
led platform to support malaria elimination in the Asia 
Pacific region [18, 19]. APMEN brings together a wide 
range of stakeholders from across the region to support 
each other to achieve individual country targets and the 
long term collective goal of regional and supra-regional 
malaria elimination [20, 21]. In November 2014 the East 
Asia Summit in Yangon, attended by 18 country repre-
sentatives, collectively committed to the elimination of 
malaria from the Asia Pacific by 2030 [22]. The achieve-
ment of such a milestone will require substantial and 
sustained political and financial commitment, as well 
as the implementation of innovative and broad reach-
ing malaria control strategies. The established APMEN 
Vivax Working Group (VxWG) provides a unique forum 
for the interdisciplinary collaboration necessary to 
achieve this, generating evidence based strategies tar-
geting P. vivax that can be translated rapidly into policy 
and practice [23]. In this article the development, activi-
ties and achievements of the VxWG are reviewed, and its 
goals, strategic processes, governance, and future direc-
tion are presented as a model for collaborative malaria 
engagement.
Establishment of the APMEN Vivax Working Group
The VxWG was established at the inaugural meeting 
of APMEN in 2009. The participants at this meeting 
included 10 National Control Programmes, numerous 
scientific and academic institutions, the World Health 
Organization (WHO), and the Australian Government. 
These founding members unanimously agreed that P. 
vivax posed a considerable challenge to malaria elimina-
tion in the Asia Pacific region, due mainly to the paucity 
of evidence required from which appropriate control 
strategies can be devised and implemented [21]. The 
APMEN VxWG was established with the mandate to 
develop and coordinate an operational research agenda 
to fill this gap [24–26] and to provide the evidence base 
for national and regional policy makers. The greatest 
burden of P. vivax is in infants and pregnant women [5, 
27]. Therefore, the VxWG agenda had direct relevance 
to achieving the Millennium Development Goals 4, 5 
and 6 current at that time. The agenda was also aligned 
with Roll Back Malaria (RBM) Global Malaria Action 
Plan (2010–2015), which encourages support of coun-
tries pursuing elimination through collection and dis-
semination of best-practice approaches, research and 
development for new tools, and provision of funding and 
technical assistance by partners. The recently released 
Global Technical Strategy for Malaria 2016–2030 [28] 
and the Action for Malaria Investment 2016–2030 [29] 
reinforce the continued relevance of the Vivax Working 
Group agenda.
By 2015, the group had grown to include representa-
tives from 18 national malaria control programmes, 
numerous P. vivax research partners, the WHO, as well 
as a variety of consortia and industry representatives.
Membership of the working group
Members are drawn from two main groups: country 
partners with key responsibilities for delivering national 
malaria control activities, and academic and research 
partner institutions. Given the group’s technical focus, 
individuals with specific expertise and responsibilities 
for vivax malaria are nominated to represent either their 
country or institution, and over time the individuals have 
often changed. The primary aim of this collaborative 
interaction is to ensure that the working group conducts 
quality research with sound methodology, relevant to the 
needs of national programmes and regional elimination 
commitments.
The Working Group is supported by a coordinating 
team, including a programme coordinator and three 
part time research scientists. Additional logistical, advo-
cacy and governance support is provided by the APMEN 
secretariat team. The work is funded by the Department 
of Foreign Affairs and Trade—Australian Aid Program 
(DFAT-APP, Australia) with additional support from the 
Bill and Melinda Gates Foundation (BMGF, USA) and 
financial and in-kind contributions from Partner Insti-
tutions and increasingly Country Partners. The Work-
ing Group members are listed in Additional file 1: Table 
S1 and the process of becoming a member is outlined in 
Additional file 2: Table S2.
Approach to research and to influencing policy 
and practice
The Working Group’s activities are geared to address key 
questions defined by the APMEN Country Partners and 
are closely aligned with the recent WHO technical brief 
on vivax malaria [30]. These activities can be directly 
relevant to operational research, but can also include 
more upstream research that will ultimately supply path-
ways to achieve these end goals. The Working Group’s 
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programme responds to the needs of countries as they 
move through the different stages of elimination and is 
responsive to new developments and opportunities. The 
process can be summarized by the following four-phase 
cycle (Fig. 1):
1. The Working Group Identifies key knowledge gaps 
through systematic literature reviews and consulta-
tions with national control programmes and aca-
demic experts.
2. Building consensus, involves setting common agen-
das, developing projects and partnerships to address 
the key knowledge gaps which have been identified. 
Annual workshops, meetings and consultations are a 
critical part of this work.
3. The Evidence required to address the identified 
knowledge gaps is then generated through a coordi-
nated programme funded directly by APMEN or by 
funding partners. The Working Group Coordinat-
ing Team provides technical support in the design, 
conduct and interpretation of small to medium sized 
research projects.
4. The fourth phase is the translation, where appropri-
ate, of evidence into recommendations that influence 
change in policy.
Identifying knowledge gaps
To date, the Working Group has conducted four sys-
tematic reviews. These include a review of the status of 
malaria research activities in member countries [31], the 
evidence on clinical efficacy of primaquine treatment 
options [32], key knowledge gaps for G6PD diagnostics 
[17] and the evidence for defining drug resistance in 
vivax malaria [16]. Key findings of those reviews are pre-
sented in Table 1.
Building consensus
Consensus on research priorities is achieved through 
convened workshops and annual meetings. These forums 
include Working Group partners as well as other experts 
with specific expertise relevant to the themes of research. 
The thematic focus is on country partners needs to facili-
tate conducting locally relevant research. The process of 
common decision-making includes the participation of 
Fig. 1 Cyclical works process of the VxWG. From: Asia Pacific Malaria 
Elimination Network. Targeting vivax malaria in the Asia Pacific 
2009–2014. Brisbane, Australia. Asia Pacific Malaria Elimination Net-
work; October 2014. P 15
Table 1 Key findings from the four APMEN Vivax Working Group literature reviews
Title Main findings
Trends in malaria research in 11 Asian Pacific countries: an analysis  
of peer-reviewed publications over two decades
Between 1990 and 2009, there had been a significant decline in the pro-
portion of malaria-related literature amongst all biomedical publications 
in the Asia-Pacific region [31].
Primaquine radical cure of Plasmodium vivax: a critical review  
of the literature
Treatment with low dose primaquine is not consistently effective in all 
areas. A higher dose of primaquine offers significant benefits in efficacy 
however these doses need to be confirmed in a range of endemic 
settings, and amongst high-risk patients. Multi-site trials are needed to 
assess higher doses of primaquine with a control arm, and careful and 
long-term patient follow up [32].
Review of key knowledge gaps in glucose-6-phosphate dehydrogenase 
deficiency detection with regard to the safe clinical deployment of 
8-aminoquinoline treatment regimens: a workshop report
Improved diagnostics for G6PD deficiency are required to facilitate the 
broader, safe and effective use of primaquine. Current methods are 
impractical in areas with limited resources, and where most malaria 
patients live [17].
Global extent of chloroquine-resistant Plasmodium vivax: a systematic 
review and meta-analysis
Enhanced monitoring and better surveillance tools are needed to assess 
the burden of P. vivax malaria, identify areas of infection and drug resist-
ance, and quantify changes in drug resistance patterns. Up to date infor-
mation is critical to ensure optimal treatment recommendations [16].
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all members and is critical to the success of the group. All 
recommendations of the Working Group are reviewed by 
APMEN Advisory Board [33] before being tabled for for-
mal voting endorsement by the Country Partners either 
at the Annual Business meeting or through electronic 
ballot. The board consists of three country partners and 
two partner institutions with voting rights; non-voting 
members are also present including representatives 
from WHO, the APMEN secretariat and funding bod-
ies. Building consensus through exchange of ideas and 
sharing experience fosters collaboration and ensures that 
planned projects incorporate both innovative research 
approaches and the practical realities of implementation. 
Working within the APMEN structures and voting mech-
anisms ensures the evidence gathered is readily available 
and relevant to National Programmes. To date the net-
work has convened eight workshops to promote dialogue 
and strive for consensus on approaches, methodologies 
and data sharing. Further details can be found in the 
Additional file 3: Table S3.
The process of engagement, collaboration and consen-
sus is demonstrated in its application to parasite surveil-
lance. Several countries in the later stages of elimination 
stressed the need to examine the potential of parasite 
genotyping to inform public policy interventions. In 
response, the first round of research projects funded by 
APMEN supported a large number of projects to geno-
type local P. vivax parasite populations in China, Indone-
sia, Malaysia, Republic of Korea, Sri Lanka and Bhutan. 
Although the projects had merit on their own, they were 
strengthened by the opportunity to compare genotyping 
datasets among the countries as well as within each indi-
vidual study area. These comparisons required a consen-
sus on genotyping methods, including internal standards, 
quality control and an appropriate platform for data shar-
ing and standardized analysis. In response, a P. vivax gen-
otyping workshop was held in 2011 in Sabah, Malaysia, 
to coordinate research activities amongst the Country 
Partners and develop consensus methods for genotyping. 
The partners agreed to use fragment size analyses of a set 
of 9 previously described short tandem repeat markers 
(MS1, MS5, MS8, MS10, MS12, MS16, MS20, pv3.27 and 
msp1F3) and to type a set of “standard” P. vivax samples 
to facilitate standardization of allele calling between dif-
ferent laboratories. A year later a second workshop was 
held in Incheon, Republic of Korea, to facilitate data 
sharing between sites and strengthen local capacity in 
data analysis. The VivaxGEN platform was developed 
to facilitate standardized allele calling and genotyping 
analysis that had been promoted at the Incheon work-
shop. The platform is currently being used as an internal 
resource for collaborating partners. Each partner retains 
ownership of their data including decisions regarding 
data accessibility via the vivaxGEN platform. Develop-
ments are underway to enable external researchers in 
the broader vivax research community to utilize the 
platform.
Generating evidence
The Working Group endeavours to generate relevant 
evidence through the Country Partner Technical Devel-
opment Programme (Additional file  4: Table S4). The 
allocated budget for this is targeted for junior to mid-
level researchers to support research related activities 
and mentor future leaders in the field. Investments have 
been modest; most individual grants were below AUD$ 
50,000 (USD$ 40,000). Between 2010 and 2014, a wide 
range of projects was funded on the three main research 
themes of surveillance, diagnosis, and treatment (Addi-
tional file 5: Table S5, Additional file 6: Table S6).
Surveillance
Parasite surveillance activities range from quantifica-
tion of parasite prevalence to optimizing the detection 
of asymptomatic and sub-patent infections, identifying 
major reservoirs of infection, detecting transmission hot-
spots and developing robust and informative approaches 
to P. vivax genotyping. Host surveillance focuses pri-
marily on defining the prevalence of G6PD deficiency 
and variant types in individuals likely to be exposed to 
primaquine for radical cure in order to define the risk 
of drug-induced haemolysis during intensive control 
activities.
The parasite molecular surveillance programme has 
generated vigorous debate on the value of molecu-
lar approaches in informing malaria control activities. 
Whilst several countries in the earlier stages of malaria 
elimination envisage limited practical benefit of parasite 
genotyping, countries in the later stages are strongly in 
favour. Defining the parasite population genetic structure 
has potential to inform on transmission intensity [34, 35], 
geographical origin of infection (i.e. whether an infec-
tion was local or imported) [36, 37], and rapidly emerg-
ing clonal expansions associated with outbreaks [38–41]. 
Intensive research is underway to define molecular mark-
ers of P. vivax drug resistance to identify the emergence 
of drug resistant parasites [42] and prioritize sites for 
anti-malarial clinical trials. The outputs from the surveil-
lance activities can provide evidence on drug efficacy to 
support review of treatment policies and revision if war-
ranted. Innovations in molecular technologies mean that 
extensive data relevant to NMCPs can now be generated 
from small quantities of capillary blood, at continually 
declining costs.
Individual surveillance projects have limited potential 
to answer regional questions, pooling of multiple datasets 
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is, therefore, important to better understand those. Many 
of the individual surveillance projects contribute to larger 
initiatives such as the Malaria Atlas Project (MAP) [43, 
44], an APMEN partner which is collating global maps of 
malaria epidemiology [45, 46] and distribution of G6PDd 
[47] and variants [48]. MAP is a prime example of data 
sharing within and across national boundaries, with the 
VxWG providing a unique forum for mutual exchange of 
both data and methods, and the evaluation of preliminary 
mapping outputs by programme experts to ensure accu-
racy and programmatic value ahead of public release. 
The VxWG has facilitated a particularly successful col-
laboration with the Indonesian Ministry of Health [49]. 
For P. vivax molecular surveillance, the vivaxGEN plat-
form, hosted by the Eijkman Institute for Molecular Biol-
ogy and Menzies School of Health Research is another 
example of an online environment aimed at facilitating 
data sharing and comparative analysis [50]. In light of the 
challenges of highly mobile human populations, a uni-
fied approach to surveillance in the Asia-Pacific region is 
essential for successful elimination.
APMEN has funded 13 surveillance projects in five 
countries, including cross-sectional and community 
surveys adopting a variety of sampling and processing 
strategies (Additional file 5: Table S5). Table 2 describes 
examples of research outputs within the surveillance 
theme, taking into account the cyclical process of work.
Diagnostics
Several point of care tests (PoCs) are available for malaria 
diagnosis [51, 52]. Older aldolase-based RDTs have low 
sensitivity for P. vivax, but newer pLDH-based RDTs have 
high (averaging 95 %) sensitivity for P. vivax comparable 
to that of HRP2 tests for P. falciparum [51]. However the 
test formats currently in use are not P. vivax-specific [51]. 
Key challenges include the lower parasite densities of P. 
vivax in asymptomatic versus symptomatic patients that 
challenge sensitive diagnosis, and the inability of cur-
rent PoCs to identify hypnozoite carriage [53]. Hence, a 
significant proportion of P. vivax infected individuals go 
undetected and untreated [7]. In order to address this, 
the VxWG has supported the evaluation of available diag-
nostics [54]. Currently PCR assays are being developed to 
quantify sub-patent parasitaemia to identify major res-
ervoirs of infection and focus elimination activities. The 
use of loop-mediated isothermal amplification (LAMP) 
has the potential to provide robust on-site diagnosis of 
parasitaemia in areas of low malaria endemicity, but this 
Table 2 Example of the cyclical work process of the Vivax Working Group (surveillance theme)
Identify knowledge  
gaps
In the first round of the Country Partner Technical Development Programme (CPTDP) undertaken in 2011, 5 of the 11 suc-
cessful grant recipients proposed P. vivax genotyping studies. These studies were funded in China, Indonesia, Malaysia, 
South Korea and Sri Lanka. It was apparent that several of the partners shared similar objectives and challenges in the 
design and interpretation of the proposed studies. The VxWG identified the need for new strategies to monitor the impact 
of interventions on the local parasite population, identify local hotspots of transmission, and detect rapidly emerging/
outbreak strains (identified as the rapid expansion of infections with identical genotypes) early. In addition, several partners 
highlighted the need for molecular tools to confirm imported cases and determine their geographic origin; this cannot 
be addressed without an integrated, multi-country approach. The VxWG coordinating team therefore held a workshop to 
facilitate standardized methodologies.
Build consensus In 2011, a P. vivax genotyping workshop was held in Sabah, Malaysia, to identify the markers that would best address the 
partners’ needs. A consensus panel of 9 short tandem repeat markers (STR) were selected to aid characterization of P. vivax 
within-host and population diversity as this reflects parasite transmission patterns. It was agreed that more information on 
the genome-wide diversity of parasites from different countries would be needed to identify optimal geographic markers. 
Nonetheless, the data generated on the tandem repeat markers would aid a feasibility analysis of the ability to distin-
guish infections from different countries using molecular methods. In 2012, a second P. vivax genotyping workshop was 
convened in Incheon, South Korea, to discuss approaches to facilitate data analysis and data sharing between the country 
partners. The partners agreed to a custom-made web-based platform (http://www.vivaxgen.menzies.edu.au) to facilitate 
these processes.
Gather the evidence To date three of the CPTDP studies have been published. In the low endemic settings of Sabah, Malaysia, P. vivax genotyp-
ing demonstrated large clusters of identical strains emerging in the population [38]. This finding emphasized the critical 
need for parasite molecular surveillance to identify rapidly emerging strains (infections with identical genotype profiles 
at the 9 STRs) which might reflect highly adaptive strains such as drug resistant strains before they spread extensively: 
conventional surveillance methods do not address this challenge. In Central China, using samples collected in 2007–2010, 
low differentiation (frequent gene flow) was observed between parasite populations from Anhui Province, where P. vivax 
remains endemic, and neighbouring Jiangsu Province, where no local cases have been detected since 2012 [24]. This 
finding highlighted the risks of resurgence in highly mobile human populations. In Indonesia, genotyping demonstrated 
higher diversity lower differentiation in P. vivax versus P. falciparum [12], possibly reflecting greater potential for spread in 
P. vivax. The same trend was observed in the Solomon Islands in a study led by researchers at the Australian Army Malaria 
Institute (an APMEN Partner Institute) [10]. This finding further emphasized the adaptive potential of P. vivax and the need 
to maintain diligent surveillance in pre-elimination settings.
Change practice Studies using the consensus markers are currently underway in a further nine countries, including 3 remaining CPTDP stud-
ies in Bhutan, South Korea and Sri Lanka.
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approach needs optimization for the detection of P. vivax 
infection [55].
The delivery of 8-aminoquinoline based radical cure 
of P. vivax is limited by the known risk of haemolysis in 
G6PD deficient individuals. The most widely used diag-
nostic assay is the fluorescent blood spot test [56], an 
assay which requires laboratory facilities and extended 
time to perform. Intensive research and development on 
quantitative and qualitative assays is underway to pro-
vide better point of care testing that will facilitate G6PD 
testing across the spectrum of clinical environments [17, 
57–59]. The Working Group is collaborating with inter-
national experts and organizations such as PATH and the 
Foundation for Innovative New Diagnostics (FIND) to 
evaluate field-testing of novel point of care diagnostics. 
APMEN country partners were early evaluators of novel 
G6PD diagnostic tests and generated the evidence to 
inform a WHO evidence review group on G6PD testing 
for P. vivax management [60]. APMEN has funded four 
projects to evaluate rapid diagnostic tests for detection 
of P. vivax and G6PD deficiency [54, 55, 61] (Additional 
file 5: Table S5). Table 3 describes an example from the 
diagnostic theme.
Treatment
The epicentre for drug resistant P. vivax is on the island 
of New Guinea, but evidence for declining chloroquine 
(CQ) efficacy has now been reported from across the 
vivax endemic world [62, 63]. Effective detection of 
drug resistant P. vivax parasites may help to combat 
this threat if timely changes in treatment policy can 
be implemented. Interpretation of the extent of CQ 
resistant P. vivax is challenging [42]. Declining anti-
malarial efficacy manifests in prolonged clearance time 
of blood stage parasites and an increasing risk for late 
recurrent infections. The timing of late recurrences is 
dependent upon the pharmacology of the initial treat-
ment regimen, the degree of drug resistance, and the 
level of host immunity. Plasmodium vivax treatment 
failure is, therefore, confounded not only by reinfec-
tion (in patients remaining within an area of ongo-
ing transmission), but also by relapses, arising from 
later reactivation of the dormant liver stages. Current 
molecular techniques are unable to distinguish reliably 
between these events [64–66]. This has undermined the 
definition and diagnosis of CQ resistance and inhib-
ited enthusiasm for generation of routine surveillance 
data. In the absence of evidence to the contrary, there 
is a tendency to assume that current anti-malarial treat-
ment regimens continue to retain efficacy long after 
declining anti-malarial activity has begun to emerge. 
However, it is vital that the threat of CQ resistant P. 
vivax is acknowledged and greater resources are applied 
for developing standardized, validated and reproducible 
tools for its characterization.
The Working Group is supporting three clinical trials in 
Bhutan, Malaysia, and Vanuatu and the Solomon Islands 
(Additional file 5: Table S5). These trials are undertaken 
in regions with little or no prior experience in the con-
duct of clinical trials, and with limited resources. The 
aim is to build capacity to conduct valid clinical trials and 
apply standardization methodologies for the assessment 
of CQ resistant P. vivax. Table  4 describes an example 
from the treatment theme.
Table 3 Example of the cyclical work process of the Vivax Working Group (diagnostic theme)
Identify knowledge gaps In May 2012 the VxWG convened a workshop in Incheon, Korea to identify key knowledge gaps in the detection of G6PD 
deficiency [17]. The lack of robust evidence for the distribution of G6PD deficiency, and the relationship of G6PD deficiency 
and drug-induced haemolysis was discussed. Without reliable, convenient and sensitive point of care diagnostics, pri-
maquine radical cure is often not prescribed, undermining P. vivax elimination efforts.
Build consensus The group identified 10 key areas that are of highest research priorities, including: the mapping of G6PD deficiency, under-
standing drug induced haemolysis in G6PD deficient individuals, the identification of desirable test characteristics and the 
cost benefit analysis of routine G6PD testing.
Gather the evidence Research projects in Cambodia, the Republic of Korea [54], Indonesia, the Philippines and China are currently being sup-
ported by the VxWG to address the identified research priorities.
One of the hot spots of vivax malaria in Hainan, a province in southern China, is home to a number of ethnic minorities. In 
contrast Jiangsu province located in Central China is mostly inhabited by Han Chinese and has witnessed a great reduc-
tion of vivax malaria over the last decades and the complete elimination of P. falciparum since 1990.
In 2013 the VxWG supported a cross sectional survey in Hainan and Jiangsu provinces to assess the population specific prev-
alence of G6PD deficiency. Participants were recruited among healthy individuals as well as febrile patients attending a 
health care facility. One drop of blood was collected from every participant together with information on the participants’ 
ethnic background. G6PD status was assessed at a reference centre applying a recently modified test assay (WST 8/1 PMS: 
methoxy PMS, Dojindo, Japan) for mass screening. Preliminary analysis indicated significant differences in the prevalence 
of G6PD deficiency between different geographic areas and ethnic groups ranging from close to 0 % to above 10 %.
Change practice The marked differences in G6PD deficiency prevalence among different ethnic groups living in close geographic proximity 
highlights the need for routine G6PD testing as part of the national treatment guidelines for the treatment of vivax malaria. 
The investigators are currently evaluating point of care diagnostics suitable for this task.
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Influencing policy and change practise
The VxWG has become a recognized forum for the intro-
duction and discussion of emerging tools and technology 
in the context of vivax elimination in the region, ensuring 
that the network partners can adopt appropriate innova-
tions and technologies in a timely manner.
The Country Partner Technical Development Pro-
gramme, which provides funding for small scale 
research projects has been a major achievement of the 
Working Group. These projects have been selected to 
address priority knowledge gaps identified by Coun-
try Partners as integral to the success of their malaria 
control programmes. At least as important, the pro-
jects also build vital local capacity that ensures country 
ownership and sustainability of local research activities. 
While some projects contribute to improving techni-
cal capacity and expertise, others directly impact policy 
and practice. One such example is the clinical study in 
Malaysia (Additional file  5: Table S5; Table  4) which 
assessed the efficacy of early parasite clearance of chlo-
roquine, which is the current first line treatment and 
compared it with artesunate–mefloquine. Preliminary 
results show that high levels of chloroquine resistant P. 
vivax are now present in this region, and suggest that 
a change to a unified ACT protocol for all Plasmodium 
species may be warranted. The Malaysian Ministry of 
Health is currently reviewing their treatment guidelines 
for P. vivax.
Others projects have provide preliminary data that will 
help to secure additional funding from outside APMEN. 
For instance the study in Vanuatu (Additional file 5: Table 
S5) in which the investigators have generated pilot data 
for developing and attracting funding for a larger and 
more definitive clinical trial.
Some projects are now being scaled up to nation wide 
interventions. An example of this is a study in Bhutan 
which reviewed the introduction of an electronic surveil-
lance system using mobile phones for disease mapping 
and early diagnosis (Additional file  5: Table S5). Based 
on the performance and user acceptability reported in 
the study the Bhutanese Vector-Borne Disease Control 
Programme incorporated this novel approach into its 
national surveillance system and is rolling it out to all 
areas at risk for malaria.
Challenges of the VxWG
The VxWG has faced a number of significant chal-
lenges. The exchange of research data and methodologies 
requires group cohesion and established relationships 
between the APMEN Country Partners and Partner 
Institutions, this requires time and investment. This pro-
cess was at various times interrupted by turnover of staff 
within the NMCP and new Country Partners or Partner 
Institutions joining the network. Critical elements for 
the success of voluntary working groups are participa-
tion and engagement. Due to conflicting demands within 
both the research Partner Institutions and NMCP (such 
as a dengue outbreak or staff promotion) certain coun-
tries were not as engaged as others and this resulted in 
longer timeframes to gain group consensus.
Cross border movement of people and parasites are a 
major issue in sustaining malaria transmission, hence 
malaria elimination is dependent upon control pro-
grammes working together across international bound-
aries on common research and technical issues. The 
expansion of the network is therefore critical to the suc-
cess of the APMEN mission. Since 2009 APMEN has 
expanded from 10 founding countries to 18, as countries 
Table 4 Example of the cyclical work process of the Vivax Working Group (treatment theme)
Identify knowledge gaps Two literature reviews were conducted on the treatment of P. vivax. The first review addressed the current knowledge 
gaps for the radical cure of P. vivax infection [32]. It revealed that treatment with low dose primaquine is not consistently 
effective in all geographical areas. The review further demonstrated that higher doses of primaquine offer significant 
benefits. However there are few data available and the review therefore concluded that these findings would need to be 
confirmed in a range of endemic settings, and amongst high-risk patients. The second review was conducted to define 
the extent and evidence regarding chloroquine resistant P. vivax [16]. The review suggests that chloroquine resistance has 
been underappreciated, with evidence for reduced susceptibility in many areas where vivax is endemic. It concluded that 
standardized methodologies and the development of novel tools are required for the more precise quantification of drug 
efficacy.
Build consensus In 2011 the VxWG group convened in Jiangsu, China to discuss options for a multicentre trial assessing the efficacy of 
vivax treatment options. During the meeting the methodological challenges of crafting appropriate study designs were 
discussed, but no consensus for a common protocol was reached. Participants did, however, agree to fund 3 pilot studies 
with the aim of generating information that would guide the study design for larger multicentred trials.
Gather the evidence One of the three clinical studies was performed in Sabah, Malaysia to assess efficacy of early parasite clearance of the current 
first line treatment, chloroquine compared with the artemisinin combination therapy (ACT) artesunate–mefloquine. The 
study followed patients up for 1 year to assess efficacy of primaquine in both study arms. Preliminary results show that 
high levels of chloroquine resistant P. vivax are now present in this region, and suggest that a change to a unified ACT 
protocol for all Plasmodium species may be warranted.
Change practice Preliminary data from this study have been presented to the Malaysian Ministry of Health, and are currently under review.
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in the region made gains in controlling malaria and com-
mitted to national or subnational strategies for malaria 
elimination. Many of these new members represent 
malarious countries who contribute significantly to the 
burden of disease in the region such as India and Papua-
New Guinea, who both joined APMEN in 2015.
The Country Partner Technical Development Pro-
gramme was designed to provide the evidence to fill 
identified key knowledge gaps. However, the size of the 
funding as well as the time frame limited the scope of this 
endeavour, the translation of this knowledge into policy 
change and ultimately the impact on disease burden. 
Many country partners required significant assistance 
in increasing research capacity in order to participate in 
tackling the research questions of most importance to 
their programmes.
Finally all of the VxWG goals and indeed its very exist-
ence are dependent upon sustained funding. The uncer-
tainty about future funding from 2016 and beyond has 
made programmatic and strategic planning beyond this 
time point very difficult.
Discussion
Over the last 5 years the APMEN VxWG has established 
itself as a unique forum for national malaria control pro-
gramme managers, researchers and collaborative part-
ners to exchange ideas and discuss regionally relevant 
issues and develop innovative approaches that can be 
applied to vivax specific challenges. To the authors 
knowledge there is no other forum with a comparable 
ability to unite such diverse stakeholders working on P. 
vivax. Throughout the last few years substantial progress 
has been achieved in building relationships and trust 
within the members of the group, which are the foun-
dation for the success of the programme. APMEN and 
its Working Group are now recognized as providing an 
important complementary role to the Asia Pacific Lead-
ers Malaria Alliance (APLMA), WHO and other regional 
consortia working together towards the goal of malaria 
elimination. Evidence for optimizing malaria control 
activities is provided traditionally by research groups 
and institutions, but these are not necessarily focussed 
on the local public health priorities. Lack of communi-
cation between researchers and national malaria control 
programme officers can be a major obstacle to ensuring 
the translation of evidence into practice [67]. The diverse 
membership of the VxWG fosters open dialogue and the 
benefits offered and gained by each of the partners are 
considerable. The NMCPs can express and articulate 
the questions they need answered to effectively com-
bat malaria and encourage the research community to 
address these. Researchers can assist NMCPs in conduct-
ing and analysing well-designed research and in return 
gain insights into programmatic priorities and align 
their own research agendas accordingly. In addition, the 
Working Group provides a platform for other consortia 
such as MAP, the World Wide Antimalarial Resistance 
Network (WWARN) and public private partnerships 
such as FIND, Medicines for Malaria Venture (MMV) 
and PATH to receive feedback on product development, 
revision of target product profiles and calls for data shar-
ing for regional and global mapping.
The malaria elimination goal in the region is set for 
2030. Political commitment is now being provided 
through the APLMA, a high level advocacy platform 
aimed at accelerating political commitment to achieve 
malaria elimination in the region. It is vital that such high 
level commitment is accompanied by innovative ideas 
and feasible local solutions that can be implemented on 
the ground. APMEN is in a prime position to bridge this 
gap. The structure and the approach of the VxWG pro-
vides a model to apply similar approaches to the broader 
agenda on malaria elimination and ultimately these 
could be extended to other diseases of public health 
importance.
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